1stOncology™: Cancer Intelligence Service – Page 9855 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021

On July 6, 2021 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer, reported that Dr. Mark Erlander, chief executive officer of Cardiff Oncology, will participate in a fireside chat and virtual 1×1 investor meetings at the William Blair Biotech Focus Conference 2021 taking place virtually from July 14-15, 2021 (Press release, Cardiff Oncology, JUL 6, 2021, View Source [SID1234584650]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Details on the fireside chat can be found below.
Date: Thursday, July 15, 2021
Time: 12:00 – 12:45 PM ET
Webcast Link:
View Source

A replay of the fireside chat will be available by visiting the "Events" section of the Cardiff Oncology website after its conclusion and will be archived on the Company website for 30 days.

AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET

On July 6, 2021 AIM ImmunoTech Inc. (NYSE American: AIM) reported that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2021, to discuss recent accomplishments and upcoming milestones (Press release, AIM ImmunoTech, JUL 6, 2021, View Source [SID1234584642]). Investors and other interested parties are invited to submit questions to management prior to the call’s start via email to [email protected].

The webcast may be accessed at View Source or on the Company’s website at View Source For those unable to participate at that time, a replay of the webcast will be available until Thursday, July 14, 2022 on the Company’s website.

First Patient Dosed with Gadeta’s gamma delta TCR Cell Therapy

On July 6, 2021 Gadeta B.V., a clinical-stage company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for cancer patients, reported the dosing of the first patient with GDT-002 (formerly labelled TEG002), a potential first-in-class cellular immunotherapy for the treatment of cancer (Press release, Gadeta, JUL 6, 2021, View Source [SID1234584635]).

The multicenter phase 1/2 study in collaboration with the Dana-Farber Cancer Institute, Mass General Brigham Cancer Care and Beth Israel Deaconess Medical Center, is evaluating safety, tolerability and preliminary efficacy of GDT-002 for the treatment of multiple myeloma (MM).

"The initiation of our phase 1/2 trial of GDT-002 and the dosing of our first patient are a transformational milestone for Gadeta in its mission to provide novel treatments to patients with cancer, including MM," said Dr Marco Londei, Chief Executive Officer of Gadeta. "Despite the successes with CAR-T and related therapies, patients often develop resistance to currently approved treatments. We believe GDT-002 offers potential as a possible new treatment option for patients with multiple myeloma and potentially other liquid and solid cancers."

GDT-002 is a cell therapy product utilizing specific γδ TCR for the treatment of a wide range of cancers. The target recognized by GDT-002 is upregulated in a wide range of liquid and solid tumors, presenting great therapeutic potential. Preclinical studies have shown that GDT-002 selectively kills primary naïve and relapsed/refractory MM cells and has an activity comparable, in MM animal models, to that of BCMA CAR-T. Importantly, a broad spectrum of liquid and solid tumors is recognized by GDT-002.

Gadeta is developing a pipeline of cell therapies, utilizing tumor specific γδ TCRs. Gadeta aims to bring its novel pipeline of selected, γδ TCR-based products to the clinic, with a focus on solid tumors.

More details of the trial can be found at clinicaltrials.gov NCT04688853.

Bausch Health Companies Inc. Will Release Second-Quarter 2021 Financial Results On August 3

On July 6, 2021 Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") reported that it will release its second-quarter 2021 financial results on Tuesday, Aug. 3, 2021 (Press release, Bausch Health, JUL 6, 2021, View Source [SID1234584634]). Bausch Health will host a conference call and live web cast at 8:00 a.m. EDT to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call.

Novavax to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights on August 5, 2021

On July 6, 2021 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, reported it will report its second quarter 2021 financial results and operational highlights on Thursday, August 5, 2021, following the close of U.S. financial markets (Press release, Novavax, JUL 6, 2021, https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-second-quarter-financial-results-and-operational-highlights-on-august-5-2021-301325648.html [SID1234584633]). Details of the event and replay are as follows: